Monorova

DRUG3 trials

Sponsors

Yuhan Corporation

Conditions

ASCVDAtherosclerotic Cardiovascular DiseaseType 2 DiabetesType 2 Diabetes Mellitus

Phase 4

High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes

Yuhan CorporationAtherosclerotic Cardiovascular Disease, Type 2 Diabetes

Start: 2018-03-27End: 2021-12-31Target: 140Updated: 2020-12-14

High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients

CompletedNCT03494270

Yuhan CorporationASCVD

Start: 2018-03-18End: 2019-09-26Updated: 2019-12-30

Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM

CompletedNCT03597412

Yuhan CorporationAtherosclerotic Cardiovascular Disease, Type 2 Diabetes Mellitus

Start: 2018-10-17End: 2020-08-12Updated: 2020-12-14

Related Papers

Lipid-Lowering Efficacy of Combination Therapy With Moderate-Intensity Statin and Ezetimibe Versus High-Intensity Statin Monotherapy: A Randomized, Open-Label, Non-Inferiority Trial From Korea

Journal of Lipid and Atherosclerosis2023-01-0115 citations